Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...
Posters presented at the American Heart Association Scientific Sessions included results that show how persistent disparities ...
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback